Millipore Sigma Vibrant Logo

500609 Temozolomide - CAS 85622-93-1 - Calbiochem

Temozolomide - CAS 85622-93-1 - Calbiochem: のSDS（安全データシート）、CoA（試験成績書）およびCoQ（品質証明書）、カタログなど製品関連の技術資料を入手いただけます。

同義語: CCRG 81045, TMZ, 3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide, NSC 362856, 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide

Primary Target: DNA guanine residues
View This Product on Sigma-Aldrich
500609
価格＆在庫状況を照会

概要

Replacement Information

主要スペック表

CAS #Empirical Formula
85622-93-1C₆H₆N₆O₂

価格＆在庫状況

カタログ番号 在庫状況包装 Qty/Pk 価格 数量
5.00609.0001
在庫状況検索中…
—
現在国内在庫なし 現在国内在庫なし
現在国内在庫有り 
販売中止
在庫僅少
現在国内在庫あり
    Remaining : Will advise
      Remaining : Will advise
      注文対象外
      お問合せください
      Contact Customer Service

      		 ｶﾞﾗｽﾋﾞﾝ 50 mg
      価格を検索中…
      価格が見つかりません
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      弊社照会 詳細を表示　
      値引
      ()
       
      —
      弊社照会
      		 —
      Description
      OverviewA cell-permeable, orally bioavailable, blood-brain barrier-permeant MTIC [5-(3-methyltriazen-1-yl-)-imidazole-4-carboxamide] prodrug whose in vivo DNA alkylating activity is employed in anticancer therapy. MGMT (O6-methylguanine DNA methyl transferase) repairs TMZ-damaged DNA lesion by covalently transferring O6-methylation on guanine residues to a cysteine residue on the MGMT, forming the basis of TMZ-resistance in cancer treatment.

      Please note that the molecular weight for this compound is batch-specific due to variable water content. Please refer to the vial label or the certificate of analysis for the batch-specific molecular weight. The molecular weight provided represents the baseline molecular weight without water.
      Catalogue Number500609
      Brand Family Calbiochem®
      SynonymsCCRG 81045, TMZ, 3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide, NSC 362856, 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
      References
      ReferencesNeyns, B., et al. 2010. Cancer 116, 2868.
      Marchesi, F., et al. 2007. Pharmacol. Res. 56, 275.
      Chakravarti, A., et al. 2006. Clin. Cancer Res. 12, 4738.
      Natsume, A., et al. 2005. Cancer Res. 65, 7573.
      Jen, J.F., et al. 2000. Pharm. Res. 17, 1284.
      Product Information
      CAS number85622-93-1
      FormOff-white solid
      Hill FormulaC₆H₆N₆O₂
      Chemical formulaC₆H₆N₆O₂
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetDNA guanine residues
      Purity≥99% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      R PhraseR: 23/24/25-36/37/38-45-46

      Toxic by inhalation, in contact with skin and if swallowed.
      Irritating to eyes, respiratory system and skin.
      May cause cancer.
      May cause heritable genetic damage.
      S PhraseS: 26-36-45

      In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
      Wear suitable protective clothing.
      In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Harmful & Carcinogenic / Teratogenic
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      カタログ番号 GTIN
      5.00609.0001 04055977244991

      Documentation

      Temozolomide - CAS 85622-93-1 - Calbiochem (M)SDS

      タイトル

      英語版製品安全データシート（(M)SDS） 

      参考資料

      参考資料の概要
      Neyns, B., et al. 2010. Cancer 116, 2868.
      Marchesi, F., et al. 2007. Pharmacol. Res. 56, 275.
      Chakravarti, A., et al. 2006. Clin. Cancer Res. 12, 4738.
      Natsume, A., et al. 2005. Cancer Res. 65, 7573.
      Jen, J.F., et al. 2000. Pharm. Res. 17, 1284.
      データシート

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision10-May-2013 JSW
      SynonymsCCRG 81045, TMZ, 3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide, NSC 362856, 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
      DescriptionA cell-permeable, orally bioavailable, blood-brain barrier-permeant MTIC [5-(3-methyltriazen-1-yl-)-imidazole-4-carboxamide] prodrug whose in vivo DNA alkylating activity is employed in anticancer therapy. MGMT (O6-methylguanine DNA methyl transferase) repairs TMZ-damaged DNA lesion by covalently transferring O6-methylation on guanine residues to a cysteine residue on the MGMT, forming the basis of TMZ-resistance in cancer treatment.
      FormOff-white solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number85622-93-1
      Chemical formulaC₆H₆N₆O₂
      Structure formulaStructure formula
      Purity≥99% by HPLC
      SolubilityDMSO (25 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Harmful & Carcinogenic / Teratogenic
      ReferencesNeyns, B., et al. 2010. Cancer 116, 2868.
      Marchesi, F., et al. 2007. Pharmacol. Res. 56, 275.
      Chakravarti, A., et al. 2006. Clin. Cancer Res. 12, 4738.
      Natsume, A., et al. 2005. Cancer Res. 65, 7573.
      Jen, J.F., et al. 2000. Pharm. Res. 17, 1284.